Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Maggie Boykin

Physician Assistant Florence, SC Physician Assistant

NPI 1508327123 CMS profile 11154831

1929 Mountain Laurel Ct, Florence, SC 29505

Open in the dashboard

General payments

$13,793

789 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Maggie Boykin of Florence, SC is reported in the CMS Open Payments database as having received $13,793 across 789 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,133 163
2024 General $3,763 203
2023 General $2,841 178
2022 General $2,290 132
2021 General $1,766 113

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Maggie Boykin
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Maggie Boykin were reported at $3,133. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Maggie Boykin Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,766 $132 $37–$438 $132
2022 $2,290 $155 $48–$522 $149
2023 $2,841 $167 $52–$557 $160
2024 $3,763 $178 $55–$600 $164
2025 $3,133 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,066 124 payments
  2. Sun Pharmaceutical Industries Inc. $1,185 78 payments
  3. Novartis Pharmaceuticals Corporation $916 57 payments
  4. Pfizer Inc. $898 57 payments
  5. Amgen Inc. $879 47 payments
  6. Janssen Biotech, Inc. $832 55 payments
  7. Lilly USA, LLC $732 40 payments
  8. Incyte Corporation $722 36 payments
  9. Regeneron Healthcare Solutions, Inc. $669 33 payments
  10. Genzyme Corporation $648 33 payments
  11. Other $4,246 229 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,184 781 payments
  2. Education $609 8 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT $1,095 54 payments
  2. RINVOQ $910 52 payments
  3. Otezla $879 47 payments
  4. SKYRIZI $864 55 payments
  5. CIBINQO $802 51 payments
  6. OPZELURA $623 35 payments
  7. TREMFYA $611 42 payments
  8. ILUMYA $598 58 payments
  9. TALTZ $586 36 payments
  10. SOTYKTU $517 28 payments
  11. Other $8,672 488 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

1,192

Median for Physician Assistant: 241

Drug cost

$795,883

Median for Physician Assistant: $4,110

Branded share of claims

16%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tremfya Guselkumab Brand 13 $181,089
Dupixent Pen Dupilumab Brand 46 $173,009
Cosentyx Sensoready (2 Pens) Secukinumab Brand 18 $130,572
Taltz Autoinjector Ixekizumab Brand 11 $112,277
Otezla Apremilast Brand 20 $96,708
Dupixent Syringe Dupilumab Brand 14 $56,402
Zoryve Roflumilast Brand 11 $9,877
Clobetasol Propionate Generic 136 $5,284
Fluocinolone Acetonide Fluocinolone/Shower Cap Brand 43 $3,829
Fluorouracil Generic 41 $3,672

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$147,779

Of which drugs: $11

Medicare patients

877

Average age 75

Services billed

4,306

559 women, 318 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Diabetes 32%
Ischemic heart disease 22%
Chronic kidney disease 21%
Depression 21%
Atrial fibrillation 17%
COPD 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 12 14 $11

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$585 60 —
RINVOQ
$270 — —
Otezla
$266 20 —
SKYRIZI
$257 — —
SOTYKTU
$246 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

789 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record